Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-19 Cells in Relapsed/Refractory CD19+ B-ALL
NCT02924753Phase 1Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2016
- Primary completion
- Jul 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CART-19 cells in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Henan Cancer Hospital. Primary endpoint: Safety as assessed by the occurrence of study related adverse events at 6 months. Status: unknown.
02
Drugs
CART-19 cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02924753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02924753.